

Correction

Correction for “ROR nuclear receptors: structures, related diseases, and drug discovery” by Yan ZHANG, Xiao-yu LUO, Dong-hai WU, and Yong XU, which appeared in issue 1, 2015, of *Acta Pharmacol Sin* (36: 71–87; doi: 10.1038/aps.2014.120).

Two errors were found.

The compound name of No 41, “**JTE-151**”, should be changed to “**JTE compound**” in Table 1.

In page 84, right, the last paragraph,

“One patent from Japan Tobacco disclosed a series of isoxazole- or triazole-based compounds as ROR γ inverse agonists. Some of the reported compounds in the patent exhibited EC₅₀ values less than 3.0 μ mol/L in a GAL4-driven **luciferase reporter assay**^[102]. Japan Tobacco recently announced a phase I clinical trial of a ROR γ inverse agonist, JTE-151 (Figure 5C).”

The highlighted expression must be changed to

One patent from Japan Tobacco disclosed a series of isoxazole- or triazole-based compounds as ROR γ inverse agonists. Some of the reported compounds in the patent exhibited EC₅₀ values less than 3.0 μ mol/L in a GAL4-driven **luciferase reporter assay (Figure 5C)**^[102]. Japan Tobacco recently announced a phase I clinical trial of a ROR γ inverse agonist, **JTE-151**.

The authors are sorry for the errors.